Table 2.
Effects of First-line Chemotherapy for Patients with ES-SCLC
| ES-SCLC (n = 83) | % | |
|---|---|---|
| Regimen | ||
| CDDP + CPT | 5 | 6 |
| CDDP + VP-16 | 3 | 4 |
| CBDCA + VP-16 | 20 | 24 |
| AMRa | 41 | 49 |
| AMR + CPTa | 9 | 11 |
| CDDP + VP-16/AMR + CPTa | 5 | 6 |
| Cycles | ||
| 1/2 | 11/10 | 13/12 |
| 3/4 | 12/36 | 14/43 |
| 5/6 | 2/12 | 2/14 |
| Response | ||
| Complete response | 1 | 1 |
| Partial response | 45 | 54 |
| Stable disease | 10 | 12 |
| Progression disease | 10 | 12 |
| Not evaluable | 17 | 20 |
| Progressionb | ||
| Sensitive relapse | 23 | 28 |
| Refractory relapse | 60 | 72 |
| Survival, median, monthsc | ||
| PFS | 5.0 (4.5–5.5) | - |
| OS | 9.2 (7.6–10.8) | - |
| [OS for sensitive relapse] | [19.4 (12.9–25.9)] | - |
| [OS for refractory relapse] | [6.9 (6.3–7.6)] | - |
Note: ES-SCLC extensive-stage small cell lung cancer, CDDP cisplatin, CBDCA carboplatin, CPT irinotecan, VP-16 etoposide, AMR amrubicin, PFS progression free survival, OS overall survival
aIncluding patients in clinical trials
bSensitive relapse: Relapsed three months after completion of the initial therapy, Refractory relapse: Experienced disease progression within three months
c(): 95 % confidence interval